Abstract
Immunocompromised patients with various causes and degrees of immunodeficiencies, such as stem cell and solid organ transplant recipients, patients with autoimmune diseases, patients with chronic renal failure or HIV-positive patients, are at increased risk of progression from latent Mycobacterium tuberculosis infection to active disease. Therefore, screening for latent tuberculosis and preventive treatment is recommended in this patient population. Tuberculosis-specific interferon (IFN)-γ release assays (TIGRAs) lacking cross-reactivity with Mycobacterium bovis bacille Calmette-Guérin have been introduced into the routine diagnosis of latent tuberculosis infection (LTBI) in the last few years as a more specific alternative to tuberculin skin test (TST). More recent results implicate that QuantiFERON®-TB Gold in tube (QFT-G-IT; Cellestis, Carnegie, Australia) may better predict progression from latent to active disease compared with TST 1, 2.

This publication has 10 references indexed in Scilit: